Arqule Inc (NASDAQ:ARQL) Just Reported Decreased Shorts

September 16, 2018 - By Jenna Rose

ArQule, Inc. (NASDAQ:ARQL) Logo

The stock of Arqule Inc (NASDAQ:ARQL) registered a decrease of 7.62% in short interest. ARQL’s total short interest was 5.64 million shares in September as published by FINRA. Its down 7.62% from 6.10M shares, reported previously. With 1.17 million shares average volume, it will take short sellers 5 days to cover their ARQL’s short positions.

The stock increased 1.48% or $0.08 during the last trading session, reaching $5.47. About 828,423 shares traded. ArQule, Inc. (NASDAQ:ARQL) has risen 397.32% since September 16, 2017 and is uptrending. It has outperformed by 381.70% the S&P500.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $595.23 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Among 3 analysts covering Arqule (NASDAQ:ARQL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arqule had 3 analyst reports since April 5, 2018 according to SRatingsIntel. The rating was initiated by Oppenheimer with “Buy” on Monday, June 11. The stock of ArQule, Inc. (NASDAQ:ARQL) has “Buy” rating given on Thursday, April 5 by Leerink Swann. The stock has “Buy” rating by FBR Capital on Friday, June 29.

More recent ArQule, Inc. (NASDAQ:ARQL) news were published by: which released: “ArQule receives Fast Track Designation for Miransertib for the treatment of PROS” on September 13, 2018. Also published the news titled: “30 Stocks Moving In Wednesday’s Pre-Market Session” on September 12, 2018.‘s news article titled: “Analysis: Positioning to Benefit within PagSeguro Digital, ChannelAdvisor, Transocean, Arcos Dorados, Precision …” with publication date: August 21, 2018 was also an interesting one.

ArQule, Inc. (NASDAQ:ARQL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.